Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Medication Therapy Management Combined With Drug and Gene Interaction Software and Cytochrome DNA Testing Among a Population of Polypharmacy Medicare Patients

NCT02428660 is registered in ClinicalTrials.gov with Genelex Corporation as lead sponsor.

NCT NCT02428660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02428660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Medication Therapy Management Combined With Drug and Gene Interaction Software and Cytochrome DNA Testing Among a Population of Polypharmacy Medicare Patients
Lead sponsor
Genelex Corporation
Phase
Not applicable
Overall status
Completed
Start date
February 28, 2015
Completion date
February 28, 2017
Enrollment
341 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cyp2d6 polymorphism, cytochrome p450 cyp2c19 enzyme deficiency, cytochrome p450 cyp2c9 enzyme deficiency, cytochrome p450 cyp2d6 enzyme deficiency, drug metabolism, poor, cyp2c19-related, drug metabolism, poor, cyp2d6-related, extensive metabolizer due to cytochrome p450 cyp2d6 variant, poor metabolizer due to cytochrome p450 cyp2d6 variant, ultrarapid metabolizer due to cytochrome p450 cyp2d6 variant